![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Allogeneic haematopoietic stem cell transplantation (ALLO-HSCT) is a potentially curative approach to treat β-thalassemia major (β-TM).
Objective and Methods: To assess the quality of life (QOL) of patients with β-TM after ALLO-HSCT, we searched PubMed, Embase, Web of Science, and MEDLINE for articles on the quality of life (QOL) of patients with β-TM from 1 Feb 2020 to 31 Mar 2020.
Results: Our review revealed that the QOL of patients with β-TM after ALLO-HSCT from a sibling donor is higher than that of patients that received blood infusion and iron-chelating therapy. Survivors of ALLO-HSCT have a QOL as good as that of a healthy population and the ability to return to normal life. However, studies thus far are limited to investigations with a few patients with β-TM who received ALLO-HSCT of the bone marrow (BM) from a sibling donor or related donor. Graft vs. host disease, patient age, gender, sexual desire, health condition, psychological state, financial and employment stress, and social support contributed to a worse QOL after ALLO-HSCT. Medicine usage, physical therapy, and psychological intervention may help improve the decline in QOL related to ALLO-HSCT in patients with β-TM.
Conclusion: Doctors and nurses must focus on implementing medicine usage, physical therapy, and psychological intervention to improve the decline in QOL related to ALLO-HSCT.
Keywords: Quality of life, β-thalassemia major, haematopoietic stem cell transplantation, blood infusion, iron-chelating therapy, bone marrow.
Current Stem Cell Research & Therapy
Title:Quality of Life in Patients with β-thalassemia Major: Short-term and Long-term Effects After Haematopoietic Stem Cell Transplantation
Volume: 16 Issue: 8
Author(s): Lu Zhai, Yuhua Liu, Rongrui Huo, Zhaofang Pan, Juan Bin, Zhi Li, Qiaomei Tang and Jing Fan*
Affiliation:
- Department of Stem Cell Transplantation, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi,China
Keywords: Quality of life, β-thalassemia major, haematopoietic stem cell transplantation, blood infusion, iron-chelating therapy, bone marrow.
Abstract:
Background: Allogeneic haematopoietic stem cell transplantation (ALLO-HSCT) is a potentially curative approach to treat β-thalassemia major (β-TM).
Objective and Methods: To assess the quality of life (QOL) of patients with β-TM after ALLO-HSCT, we searched PubMed, Embase, Web of Science, and MEDLINE for articles on the quality of life (QOL) of patients with β-TM from 1 Feb 2020 to 31 Mar 2020.
Results: Our review revealed that the QOL of patients with β-TM after ALLO-HSCT from a sibling donor is higher than that of patients that received blood infusion and iron-chelating therapy. Survivors of ALLO-HSCT have a QOL as good as that of a healthy population and the ability to return to normal life. However, studies thus far are limited to investigations with a few patients with β-TM who received ALLO-HSCT of the bone marrow (BM) from a sibling donor or related donor. Graft vs. host disease, patient age, gender, sexual desire, health condition, psychological state, financial and employment stress, and social support contributed to a worse QOL after ALLO-HSCT. Medicine usage, physical therapy, and psychological intervention may help improve the decline in QOL related to ALLO-HSCT in patients with β-TM.
Conclusion: Doctors and nurses must focus on implementing medicine usage, physical therapy, and psychological intervention to improve the decline in QOL related to ALLO-HSCT.
Export Options
About this article
Cite this article as:
Zhai Lu, Liu Yuhua, Huo Rongrui, Pan Zhaofang, Bin Juan, Li Zhi, Tang Qiaomei and Fan Jing*, Quality of Life in Patients with β-thalassemia Major: Short-term and Long-term Effects After Haematopoietic Stem Cell Transplantation, Current Stem Cell Research & Therapy 2021; 16 (8) . https://dx.doi.org/10.2174/1574888X16666210203105340
DOI https://dx.doi.org/10.2174/1574888X16666210203105340 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Smart Drug Delivery Systems in Cancer Therapy
Current Drug Targets Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas
Current Pharmaceutical Design Antioxidant Supplements, Genetics and Chemotherapy Outcomes
Current Cancer Therapy Reviews Effect of Treatment with Caspofungin on the Diagnosis of Fungal Infections by Gamma Scintigraphy
Current Radiopharmaceuticals Comprehensive Comparison of Trace Metal Concentrations in Cancerous and Non-Cancerous Human Tissues
Current Medicinal Chemistry Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Development and Evaluation of Bioresponsive Tablets of a Selective COX-2 Inhibitor for Colonic Delivery
Drug Delivery Letters Diagnosis and Therapy of Autoimmune Hepatitis
Mini-Reviews in Medicinal Chemistry Potential Therapeutic Application of the Association of Vitamins C and K3 in Cancer Treatment
Current Medicinal Chemistry Editorial (Thematic Issue: Targeting Epithelial-to-Mesenchymal Transition for Cancer Therapy)
Current Pharmaceutical Design The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers
Current Cancer Drug Targets Risk Factors for In-Hospital Mortality among Cancer Patients with COVID-19: A Cross-Sectional Study
Current Respiratory Medicine Reviews Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Clinical Experience with Thalidomide and Lenalidomide in Multiple Myeloma
Current Cancer Drug Targets Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews A Conceptual View on Glucocorticoid-Induced Apoptosis, Cell Cycle Arrest and Glucocorticoid Resistance in Lymphoblastic Leukemia
Current Molecular Medicine Mechanisms Underlying Beneficial Health Effects of Tea Catechins to Improve Insulin Resistance and Endothelial Dysfunction
Endocrine, Metabolic & Immune Disorders - Drug Targets On the Origin of Epidermal Cancers
Current Molecular Medicine Tubulins - The Target for Anticancer Therapy
Current Topics in Medicinal Chemistry Increasing Sensitivity to Radiotherapy and Chemotherapy by Using Novel Biological Agents that Alter the Tumor Microenvironment
Current Molecular Medicine